DexCom 7 receives FDA approval
By HME News Staff
Updated 10:49 AM CST, Thu December 8, 2022
SAN DIEGO – DexCom has received clearance from the U.S. Food and Drug Administration for its next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System for people with all types of diabetes ages two years and older. “There’s a reason Dexcom has the best-selling real-time CGM on the market,” said Kevin Sayer, chairman, president and CEO of Dexcom. “For more than a decade, we’ve pioneered generation after generation of sensing technology that consistently delivers improved accuracy, reliability and a simpler user experience, giving people greater control of their diabetes. When we set out to design G7, our goal was simple: to make the most powerful, easy-to-use CGM available for people with diabetes, whether they have Type 1 or Type 2.” Dexcom G7 offers a suite of customizable alerts that can warn of high or low glucose levels and help users spend more time in range. The system features a predictive low alert that provides a 20-minute advance warning of potentially dangerous low glucose levels so users can act quickly to avoid a hypoglycemic event. Users can also share information with loved ones and care teams anywhere, anytime through industry-leading remote monitoring and reporting capabilities.
Comments